Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $16.9 Million - $40 Million
-3,383,170 Reduced 43.93%
4,318,700 $51.1 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $4.36 Million - $8.02 Million
954,321 Added 14.14%
7,701,870 $45.6 Million
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $261,138 - $744,313
69,823 Added 1.05%
6,747,549 $28.7 Million
Q1 2022

May 16, 2022

BUY
$7.81 - $20.45 $5.02 Million - $13.1 Million
642,851 Added 10.65%
6,677,726 $63.5 Million
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $41.6 Million - $97.2 Million
2,738,424 Added 83.07%
6,034,875 $115 Million
Q3 2021

Nov 15, 2021

BUY
$21.78 - $40.45 $10.4 Million - $19.2 Million
475,372 Added 16.85%
3,296,451 $110 Million
Q2 2021

Aug 16, 2021

SELL
$32.5 - $48.96 $4.88 Million - $7.35 Million
-150,057 Reduced 5.05%
2,821,079 $109 Million
Q1 2021

May 17, 2021

SELL
$41.61 - $54.3 $9.61 Million - $12.5 Million
-230,925 Reduced 7.21%
2,971,136 $143 Million
Q4 2020

Feb 16, 2021

SELL
$25.27 - $54.9 $30.1 Million - $65.3 Million
-1,190,135 Reduced 27.1%
3,202,061 $167 Million
Q3 2020

Nov 16, 2020

BUY
$18.49 - $27.24 $78.8 Million - $116 Million
4,262,157 Added 3277.6%
4,392,196 $118 Million
Q2 2020

Aug 14, 2020

BUY
$8.9 - $21.84 $1.16 Million - $2.84 Million
130,039 New
130,039 $2.53 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.23B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.